Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Recurrent Respiratory Papillomatosis
NCT02859454Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2016
- Primary completion
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in recurrent respiratory papillomatosis (RRP), sponsored by National Cancer Institute. Started Aug 2016; status: completed.
02
Drugs
avelumab
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT02859454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859454.